A Phase 1, First-in-Human Study of CTIM-76, a Claudin-6 (CLDN6)-Directed Bispecific Antibody, in Patients with Recurrent Ovarian Cancer and Other Advanced Solid Tumors

Publications

Jun 2

Written by Martin Lehr

CLDN6

Context Therapeutics Reports Third Quarter 2025 Operating and Financial Results

Determination of first in human dose of the T cell-redirecting bispecific antibody CT-95 targeting mesothelin and CD3